Compare ASTRAZENECA PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA PROCTER & GAMBLE HEALTH ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 129.9 62.2 208.9% View Chart
P/BV x 36.5 7.7 476.3% View Chart
Dividend Yield % 0.0 6.2 -  

Financials

 ASTRAZENECA PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
PROCTER & GAMBLE HEALTH
Dec-18
ASTRAZENECA PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs1,2783,549 36.0%   
Low Rs8831,301 67.8%   
Sales per share (Unadj.) Rs228.4511.4 44.7%  
Earnings per share (Unadj.) Rs10.461.3 16.9%  
Cash flow per share (Unadj.) Rs16.374.0 22.0%  
Dividends per share (Unadj.) Rs0440.00 0.0%  
Dividend yield (eoy) %018.1 0.0%  
Book value per share (Unadj.) Rs98.8927.8 10.6%  
Shares outstanding (eoy) m25.0016.60 150.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.74.7 99.7%   
Avg P/E ratio x104.239.6 263.4%  
P/CF ratio (eoy) x66.432.8 202.8%  
Price / Book Value ratio x10.92.6 418.4%  
Dividend payout %0717.9 0.0%   
Avg Mkt Cap Rs m27,00840,257 67.1%   
No. of employees `0001.41.1 119.6%   
Total wages/salary Rs m1,5351,313 117.0%   
Avg. sales/employee Rs Th4,210.97,486.7 56.2%   
Avg. wages/employee Rs Th1,132.21,157.6 97.8%   
Avg. net profit/employee Rs Th191.1897.2 21.3%   
INCOME DATA
Net Sales Rs m5,7108,490 67.3%  
Other income Rs m123244 50.2%   
Total revenues Rs m5,8338,734 66.8%   
Gross profit Rs m4631,482 31.2%  
Depreciation Rs m147211 69.8%   
Interest Rs m00-   
Profit before tax Rs m4381,514 28.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m066 0.0%   
Tax Rs m179563 31.8%   
Profit after tax Rs m2591,017 25.5%  
Gross profit margin %8.117.5 46.5%  
Effective tax rate %40.837.1 110.0%   
Net profit margin %4.512.0 37.9%  
BALANCE SHEET DATA
Current assets Rs m3,20915,343 20.9%   
Current liabilities Rs m2,0701,960 105.6%   
Net working cap to sales %20.0157.6 12.7%  
Current ratio x1.67.8 19.8%  
Inventory Days Days7249 148.4%  
Debtors Days Days3528 122.8%  
Net fixed assets Rs m7901,209 65.4%   
Share capital Rs m50166 30.1%   
"Free" reserves Rs m2,41915,235 15.9%   
Net worth Rs m2,46915,401 16.0%   
Long term debt Rs m00-   
Total assets Rs m4,60517,595 26.2%  
Interest coverage xNMNM-  
Debt to equity ratio x00-  
Sales to assets ratio x1.20.5 256.9%   
Return on assets %5.65.8 97.3%  
Return on equity %10.56.6 158.8%  
Return on capital %17.710.3 172.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3001,636 18.3%   
Fx outflow Rs m2,0154,368 46.1%   
Net fx Rs m-1,715-2,732 62.8%   
CASH FLOW
From Operations Rs m88-1,304 -6.7%  
From Investments Rs m-9412,697 -0.7%  
From Financial Activity Rs mNA-301 0.0%  
Net Cashflow Rs m-611,093 -0.1%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 51.8 144.8%  
Indian inst/Mut Fund % 0.3 18.2 1.6%  
FIIs % 15.7 1.0 1,570.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 29.1 31.3%  
Shareholders   12,856 28,591 45.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  SUVEN LIFE SCIENCES  

Compare ASTRAZENECA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Open Higher; Bajaj Finance & UltraTech Cement Top Gainers(09:30 am)

Asian stock markets are trading on a strong note today. The Hang Seng is trading up by 2% while the Shanghai Composite is up 0.6%. The Nikkei is trading higher by 0.4%.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY21); Net Profit Up 57.0% (Quarterly Result Update)

Aug 31, 2020 | Updated on Aug 31, 2020

For the quarter ended June 2020, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 692 m (up 57.0% YoY). Sales on the other hand came in at Rs 6 bn (up 171.6% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (2QFY20); Net Profit Down 13.0% (Quarterly Result Update)

Nov 14, 2019 | Updated on Nov 14, 2019

For the quarter ended September 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 358 m (down 13.0% YoY). Sales on the other hand came in at Rs 2 bn (down 0.4% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

PROCTER & GAMBLE HEALTH Announces Quarterly Results (1QFY20); Net Profit Up 34.3% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PROCTER & GAMBLE HEALTH has posted a net profit of Rs 441 m (up 34.3% YoY). Sales on the other hand came in at Rs 2 bn (up 6.1% YoY). Read on for a complete analysis of PROCTER & GAMBLE HEALTH's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

Buzzing Sectors Before Budget 2021(Fast Profits Daily)

Jan 12, 2021

The budget is just a few weeks away. Which stocks can you expect to move? Find out in this video.

Here's Why Smallcaps Could Be Your Best Investment in 2021(Profit Hunter)

Jan 12, 2021

Select smallcaps hold a great potential to become the multibaggers of tomorrow. Here's how you could get in early into these stocks.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Jan 25, 2021 09:54 AM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 5-YR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS